Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024
Mineralys Therapeutics to Announce First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 9, 2024
RADNOR, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by dysregulated aldosterone, today announced it will report its financial results from the first quarter ended March 31, 2024, before the financial markets open on Thursday, May 9, 2024.
賓夕法尼亞州拉德諾，2024年5月2日（GLOBE NEWSWIRE）——專注於開發針對高血壓、慢性腎臟病（CKD）和其他由醛固酮失控引起的疾病的藥物的臨床階段生物製藥公司Mineralys Therapeutics, Inc.（納斯達克股票代碼：MLYS）今天宣佈，將在週四金融市場開盤前公佈截至2024年3月31日的第一季度財務業績，2024 年 5 月 9 日。
| Thursday, May 9th @ 8:30 a.m. ET | |
| Domestic: | 1-888-886-7786 |
| International: | 1-416-764-8658 |
| Conference ID: | 93715931 |
| Webcast: | Link |
| 5月9日，星期四第四 @ 美國東部時間上午 8:30 | |
| 國內： | 1-888-886-7786 |
| 國際： | 1-416-764-8658 |
| 會議編號： | 93715931 |
| 網絡直播： | 鏈接 |
Participants can use the dial-in information above or choose the Call me option (click here) for instant telephone access to the event which will be made active 15 minutes prior to the scheduled start time. A live webcast of the conference call may be found here or on the "News & Events" page in the Investor Relations section of the Mineralys Therapeutics website.
參與者可以使用上面的撥入信息，也可以選擇 “給我打電話” 選項（單擊此處）以即時電話訪問活動，活動將在預定開始時間前 15 分鐘激活。可以在此處或Mineralys Therapeutics網站投資者關係部分的 “新聞與活動” 頁面上找到電話會議的網絡直播。
About Mineralys Therapeutics
關於 Mineralys 療法
Mineralys Therapeutics is a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, CKD and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is a proprietary, orally administered, highly selective aldosterone synthase inhibitor that Mineralys Therapeutics is developing for cardiorenal conditions affected by dysregulated aldosterone, including hypertension and CKD. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit Follow Mineralys on LinkedIn and Twitter.
Mineralys Therapeutics是一家臨床階段的生物製藥公司，專注於開發針對高血壓、慢性腎病和其他由醛固酮失調引起的疾病的藥物。其最初的候選產品lorundrostat是一種專有的、口服給藥的高選擇性醛固酮合酶抑制劑，Mineralys Therapeutics正在開發該抑制劑，用於受醛固酮失調影響的心腎疾病，包括高血壓和慢性腎病。Mineralys總部位於賓夕法尼亞州的拉德諾，由Catalys Pacific創立。欲了解更多信息，請訪問領英和推特上關注Mineralys。
Contact:
Investor Relations
investorrelations@mineralystx.com
聯繫人：
投資者關係
investorrelations@mineralystx.com
Media Relations
Tom Weible
Elixir Health Public Relations
Phone: (1) 515-707-9678
Email: tweible@elixirhealthpr.com
媒體關係
湯姆·韋布爾
Elixir Health 公共關係
電話：(1) 515-707-9678
電子郵件：tweible@elixirhealthpr.com
譯文內容由第三人軟體翻譯。